⏳ Fetching live dividend data...
Home › Calculator › ARYX Dividend Calculator 2026
ARYx Therapeutics, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ARYX → $1.051200391086941e+34M in 10 years · $875,781,380,560,643,900,000,000,000,000,000,000,000.00/month
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company's other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime.
Ready to invest? Open ARYX position with:
Real after-tax yield depends on where you live and how you hold ARYX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 400000.00% | 399997.20% | $40,000,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 340000.00% | 339997.20% | $34,000,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 320000.00% | 319997.20% | $32,000,000 / yr |
| 🇬🇧 UK ISA | 0% | 400000.00% | 399997.20% | $40,000,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 365000.00% | 364997.20% | $36,500,000 / yr |
| 🇨🇦 TFSA | 0% | 400000.00% | 399997.20% | $40,000,000 / yr |
| 🇨🇦 CA Taxable | 25% | 300000.00% | 299997.20% | $30,000,000 / yr |
| 🇦🇺 Super (pension) | 15% | 340000.00% | 339997.20% | $34,000,000 / yr |
| 🇦🇺 AU Taxable | 30% | 280000.00% | 279997.20% | $28,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 294500.00% | 294497.20% | $29,450,000 / yr |
| 🇫🇷 FR Taxable | 30% | 280000.00% | 279997.20% | $28,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ARYX pays quarterly — 4 times per year. Next ex-div: TBD.
How ARYX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ARYX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2011-03-10 | 4,469,274 | $0.07 | $326.3K | ||
| Sale | 2011-03-10 | 4,469,274 | $0.07 | $326.3K | ||
| Sale | 2011-03-10 | 4,469,274 | $0.07 | $326.3K | ||
| Sale | 2011-03-10 | 4,469,274 | $0.07 | $326.3K | ||
| Buy | 2010-09-30 | 500,000 | $0.50 | $250.0K | ||
| Buy | 2010-09-30 | 500,000 | $0.50 | $250.0K | ||
| Buy | 2010-09-30 | 500,000 | $0.50 | $250.0K | ||
| Buy | 2010-08-13 | 500,000 | $0.50 | $250.0K | ||
| Buy | 2010-08-13 | 500,000 | $0.50 | $250.0K | ||
| Buy | 2010-08-13 | 500,000 | $0.50 | $250.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ARYX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →